Transcode Therapeutics Inc.
13F holders, Q3 2024 (September 30)10holders −5
3new positions
8sold out
$0.57avg. 13F price*
At the end of Q3 2024, 10 institutions reported holding Transcode Therapeutics Inc. in their 13F filings, down 5 from Q2 2024. 3 opened new positions and 8 sold out. The largest holders were Geode Capital Management, LLC ($70K), Private Capital Management LLC ($46K) and Sheets Smith Wealth Management ($29K).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L303
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $23K |
| Exits | 8 | $157K |
All 13F filers, Q2 2024 → Q3 2024: 221,496 shares bought and 158,302 shares sold, net +63,194 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Geode Capital Management, LLC | 0.00% | Add +217.1% | 121,768 | $70K |
| Private Capital Management LLC | 0.01% | Add +360.5% | 80,675 | $46K |
| Sheets Smith Wealth Management | 0.00% | Add +149.0% | 50,138 | $29K |
| Jane Street Group, LLC | 0.00% | New | 39,706 | $23K |
| Captrust Financial Advisors | 0.00% | Add +44.4% | 16,250 | $9K |
| Morgan Stanley | 0.00% | No change | 10,000 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -17.8% | 6,474 | $4K |
| FMR LLC | 0.00% | New | 175 | $100 |
| Bank of America Corp. | 0.00% | Add +156.4% | 141 | $81 |
| Danske Bank A/S | 0.00% | New | 2 | $1 |
"% of holder's portfolio" is TRANSCODE THERAPEUTICS INC's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.